Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$2.33 +9.9%	$2.59	$1.14 ▼ $7.20	$139.56M	0.92	798,487 shs	595,498 shs
BCAX Bicara Therapeutics	$11.11 +12.2%	$12.48	$7.80 ▼ $28.09	$605.90M	N/A	559,876 shs	1.50 million shs
ETON Eton Pharmaceuticals	$17.56 -6.8%	$15.92	$3.18 ▼ $21.48	$470.92M	1.22	206,508 shs	409,854 shs
STOK Stoke Therapeutics	$10.40 +4.9%	$8.44	$5.35 ▼ $17.58	$567.81M	1.2	701,358 shs	379,755 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-1.85%	-4.50%	-24.56%	-65.64%	-45.08%
BCAX Bicara Therapeutics	+6.68%	+6.80%	-31.72%	-27.58%	+989,999,900.00%
ETON Eton Pharmaceuticals	-0.32%	-4.90%	+8.65%	+24.11%	+430.70%
STOK Stoke Therapeutics	+3.12%	+5.88%	+2.91%	+30.74%	-32.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.6979 of 5 stars	3.5	3.0	0.0	2.9	1.7	0.6
BCAX Bicara Therapeutics	1.7185 of 5 stars	3.5	0.0	0.0	1.6	0.8	0.6
ETON Eton Pharmaceuticals	3.2848 of 5 stars	3.5	5.0	0.0	3.9	0.8	0.6
STOK Stoke Therapeutics	4.0538 of 5 stars	3.6	2.0	4.8	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	307.73% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	186.76% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	68.94% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	123.08% Upside

Current Analyst Ratings Breakdown

Latest ALDX, ETON, STOK, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	$48.33M	9.74	$0.00 per share	4,502.79	$0.60 per share	29.27
STOK Stoke Therapeutics	$190.91M	2.97	N/A	N/A	$3.57 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$37.54M	-$0.97	N/A	N/A	N/A	N/A	-43.01%	-33.62%	7/30/2025 (Estimated)
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
ETON Eton Pharmaceuticals	-$940K	-$0.18	N/A	35.12	N/A	-15.81%	-36.29%	-16.84%	8/14/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	$0.79	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	8/5/2025 (Estimated)

Latest ALDX, ETON, STOK, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million
3/18/2025	Q4 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.02	N/A	-$0.02	$10.53 million	$11.65 million
3/6/2025	Q4 2024	ALDX Aldeyra Therapeutics	$0.03	-$0.27	-$0.30	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.18	6.80	6.80
BCAX Bicara Therapeutics	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	1.51	1.41
STOK Stoke Therapeutics	N/A	5.09	5.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
BCAX Bicara Therapeutics	N/A
ETON Eton Pharmaceuticals	27.86%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
BCAX Bicara Therapeutics	15.50%
ETON Eton Pharmaceuticals	16.03%
STOK Stoke Therapeutics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.49 million	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
ETON Eton Pharmaceuticals	20	26.82 million	22.17 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	46.98 million	Optionable

ALDX, ETON, STOK, and BCAX Headlines

Recent News About These Companies

Financial Review: Renovaro (NASDAQ:RENB) & Stoke Therapeutics (NASDAQ:STOK)

June 2 at 2:25 AM | americanbankingnews.com

Voloridge Investment Management LLC Sells 36,261 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 31 at 3:56 AM | marketbeat.com

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2025 | businesswire.com

D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 29, 2025 | marketbeat.com

Toronto Dominion Bank Invests $35 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 28, 2025 | marketbeat.com

Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics

May 27, 2025 | fiercebiotech.com

Deutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 22, 2025 | marketbeat.com

Toronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 21, 2025 | marketbeat.com

Tang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 20, 2025 | marketbeat.com

Chardan Capital Has Strong Forecast for STOK FY2025 Earnings

May 20, 2025 | marketbeat.com

RTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 18, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald

May 17, 2025 | marketbeat.com

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

May 16, 2025 | zacks.com

MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 16, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings Beat

May 15, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

May 13, 2025 | zacks.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP

May 13, 2025 | marketbeat.com

Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 12, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages

May 12, 2025 | marketbeat.com

DAFNA Capital Management LLC Has $1.89 Million Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 10, 2025 | marketbeat.com

Baker BROS. Advisors LP Increases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, ETON, STOK, and BCAX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$2.33 +0.21 (+9.91%)

As of 12:40 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Bicara Therapeutics NASDAQ:BCAX

$11.11 +1.21 (+12.22%)

As of 12:40 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Eton Pharmaceuticals NASDAQ:ETON

$17.56 -1.28 (-6.79%)

As of 12:39 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Stoke Therapeutics NASDAQ:STOK

$10.40 +0.49 (+4.94%)

As of 12:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time